Predicting Liver Cancer Treatment Response with Blood Markers
Author Information
Author(s): Kohles Nikolaus, Nagel Dorothea, Jüngst Dietrich, Durner Jürgen, Stieber Petra, Holdenrieder Stefan
Primary Institution: University-Hospital Munich-Grosshadern, Germany
Hypothesis
Can circulating nucleosomes and oncological biomarkers predict the response to transarterial chemoembolization therapy in liver cancer patients?
Conclusion
Circulating nucleosomes and liver markers are valuable tools for early estimation of the efficacy of TACE therapy in HCC patients.
Supporting Evidence
- Nucleosomes and liver markers increased significantly after TACE.
- The combination of nucleosomes and alkaline phosphatase was predictive of therapy response.
- The study included 50 patients with a total of 77 TACE treatments.
Takeaway
Doctors can use certain blood markers to see how well liver cancer treatment is working, helping them make better decisions sooner.
Methodology
Blood samples were taken from 50 liver cancer patients before and after TACE therapy to analyze various biomarkers and compare them with therapy response.
Potential Biases
Potential bias due to the exclusion of treatments accompanied by RFA and variability in patient follow-up.
Limitations
The study had a limited number of patients and variability in the timing of therapy response evaluations.
Participant Demographics
42 males and 8 females, mean age 66.7 years, with 74% having cirrhosis.
Statistical Information
P-Value
< 0.001
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website